060 | Intellipharmaceutics’ face lawsuit over tamper resistant opioid, IDT tackles CRISPR off-targets

by • August 8, 2017 • Feature Slider, Feature-Home, Featured-Slides-HomeComments Off on 060 | Intellipharmaceutics’ face lawsuit over tamper resistant opioid, IDT tackles CRISPR off-targets149

In this episode, we discuss the ups and down of an Ontario-based pharma company seeking to develop a solution for the world’s deadly opioid epidemic, and the milestones reached by a custom DNA nucleotide maker that has locked its sights on the problem of CRISP Cas9 off-targets.

To read the full stories, click on the links below:

Intellipharmaceutics faces lawsuit over Rexista

IDT launches Cas9 enzyme which cuts down CRISPR off-targets

Comments are closed.